

Paul A Hamlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2155215/publications.pdf>

Version: 2024-02-01

70
papers

1,831
citations

394421

19
h-index

276875

41
g-index

70
all docs

70
docs citations

70
times ranked

2748
citing authors

#	ARTICLE	IF	CITATIONS
1	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1144-1152.	3.5	6
2	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
3	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	1.7	6
4	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
5	Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. <i>Cancer Research Communications</i> , 2022, 2, 307-315.	1.7	2
6	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
7	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Blood Advances</i> , 2021, 5, 345-351.	5.2	7
8	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
9	Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2608-2618.	5.2	22
10	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	4.1	16
11	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	5.2	15
12	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
13	Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 2423-2423.	1.4	3
14	Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 622-622.	1.4	5
15	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	1.4	0
16	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.	1.4	0
17	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
18	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81

#	ARTICLE	IF	CITATIONS
19	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3382-3390.	5.2	10
20	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2331-2334.	2.4	0
21	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	2.8	21
22	The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1833-1841.	1.3	9
23	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
24	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
25	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
26	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
27	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	3.5	17
28	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
29	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. <i>American Journal of Hematology</i> , 2019, 94, E90-E93.	4.1	23
30	A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 466-466.	1.4	18
31	Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab. <i>Blood</i> , 2019, 134, 3981-3981.	1.4	5
32	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2837-2837.	1.4	6
33	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1555-1555.	1.4	4
34	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	1.4	9
35	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2904-2904.	1.4	2
36	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25

#	ARTICLE	IF	CITATIONS
37	Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2133-2138.	2.0	24
38	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
39	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
40	Primary Mediastinal B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S170-S173.	0.4	0
41	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	1.4	3
42	Central nervous system involvement in T-cell lymphoma: A single center experience. <i>Acta Oncologica</i> , 2016, 55, 561-566.	1.8	44
43	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
44	Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma. <i>Lancet Oncology</i> , The, 2016, 17, 1023-1025.	10.7	3
45	Prospective Study of ¹⁸ F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	5.0	41
46	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	1.4	2
47	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). <i>Blood</i> , 2016, 128, 1778-1778.	1.4	3
48	Outcome of Initial Observation in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1803-1803.	1.4	3
49	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
50	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	1.4	21
51	Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/II Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL). <i>Blood</i> , 2016, 128, 4200-4200.	1.4	3
52	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	1.4	0
53	A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. <i>Tumor Microenvironment and Therapy</i> , 2015, 2, 14-18.	1.2	3
54	Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies. <i>Blood</i> , 2015, 126, 3929-3929.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL). <i>Blood</i> , 2015, 126, 5112-5112.	1.4	1
56	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	1.4	0
57	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2691-2691.	1.4	0
58	Treatment Patterns and Comparative Effectiveness in Elderly Diffuse Large B-Cell Lymphoma Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2014, 19, 1249-1257.	3.7	54
59	Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2004-2009.	2.0	52
60	Evolving Treatment Paradigms for Primary Mediastinal Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1751-1753.	1.6	7
61	Personalizing Therapy for Older Adults with Lymphoid Malignancies: Options and Obstacles. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e240-e248.	3.8	3
62	Is Maintenance Rituximab Now Ready for PRIMA-Time?. <i>Current Oncology Reports</i> , 2010, 12, 355-357.	4.0	2
63	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1896-1903.	1.6	293
64	Meta-analysis: Making sense of maintenance rituximab?. <i>Current Oncology Reports</i> , 2009, 11, 329-330.	4.0	0
65	Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.. <i>Blood</i> , 2007, 110, 1893-1893.	1.4	0
66	Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.. <i>Blood</i> , 2006, 108, 3057-3057.	1.4	5
67	Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. <i>British Journal of Haematology</i> , 2005, 130, 691-699.	2.5	123
68	Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999.. <i>Blood</i> , 2004, 104, 614-614.	1.4	4
69	The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT.. <i>Blood</i> , 2004, 104, 10-10.	1.4	12
70	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 102, 1989-1996.	1.4	235